| Overview |
| bs-9441R |
| KChIP2 Polyclonal Antibody |
| WB, IHC-P, IF(IHC-P) |
| Human, Mouse, Rat |
| Specifications |
| Unconjugated |
| Rabbit |
| KLH conjugated synthetic peptide derived from human KChIP2 |
| 1-100/270 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles. |
| Target |
| 30819 |
| KCNIP-2; A type potassium channel modulatory protein 2; A-type potassium channel modulatory protein 2; Cardiac voltage gated potassium channel modulatory subunit; Cardiac voltage-gated potassium channel modulatory subunit; DKFZp566L1246; KChIP 2; KChIP2; KCIP2_HUMAN; KCNIP 2; Kcnip2; Kv channel interacting protein 2; Kv channel-interacting protein 2; MGC17241; Potassium channel interacting protein 2; Potassium channel-interacting protein 2. |
| The downstream regulatory element, DRE, acts as a location-dependent gene silencer. DREAM (for DRE-antagonist modulator) is a Ca2+-regulated transcriptional repressor that specifically binds to the DRE. DREAM regulates transcription of prodynorphin and c-Fos genes and shows 99% nucleotide homology to the Kv channel-interacting proteins (KChIPs). KChIP family members include KChIP1, which is expressed in brain, KChIP2, which is expressed in heart, brain, and lung, KChIP3 (also designated calsenilin), which is expressed in brain and testis and KChIP4. |
| Application Dilution |
| WB |
1:300-5000 |
| IHC-P |
1:200-400 |
| IF(IHC-P) |
1:50-200 |
Powered by Bioz